share_log

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

查丹资本维持对Sonnet BioTherapeutics的买入,将目标股价下调至14美元
Benzinga ·  2023/05/11 05:21

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $17 to $14.

Chardan Capital分析师Keay Nakae维持Sonnet BioTherapeutics(纳斯达克股票代码:SONN)的买入,并将目标股价从17美元下调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发